Abstract 285P
Background
Adjuvant ET reduces breast cancer recurrence and increases overall survival among patients with early-stage ER+ breast cancer, however a suboptimal number of patients older than 65 years are included in the studies. This study aims to evaluate adherence to adjuvant ET and sexual dysfunction in women >65 years old with early breast cancer.
Methods
Women with a history of early-stage ER+ invasive carcinoma of the breast on adjuvant ET for at least 6 months were invited to participate. Adherence was assessed with Morisky Medication Adherence Scale (MMAS-8). Quality of life was assessed using EORTC QLQ C30 and BR-23 forms. Sexuality was assessed with the Female Sex Function Index questionnaire. Patients were stratified according to age <=65 years and > 65 years old. Qualitative variables were compared between groups using the Chi-square or exact Chi-square test and for quantitative variables the non-parametric Mann-Whitney test was used.
Results
From June 2021 to March 2024, 774 women from 15 Brazilian institutions were recruited. Mean age was 62 y.o, mean tumor size was 2.24 cm, mean duration of ET was 3.2y. About 191 patients (24.7%) were older than 65y, 69.6% of them were high adherent to ET and 70.7% had sexual dysfunction. In comparison with women <=65 y.o, older women were associated with private healthcare insurance (p=0.003), living with no partner (p < 0.0001), prior lumpectomy (p = 0.0017), prior sentinel node biopsy (p = 0.03), no prior chemotherapy (p < 0.0001), use of aromatase inhibitors (p < 0.0001) and use of concomitant medications (p < 0,0001). Patients older than 65 years were more associated with lower adherence (p = 0.0009), but there was no difference in sexual dysfunction in comparison with patients less than 65 y. Patients over 65 years had significantly higher scores for Emotional Functioning, Cognitive Functioning, Social Functioning, Body Image and Future Perspective domains of quality of life.
Conclusions
Patients older than 65 y.o had less aggressive treatments, many better domains in quality of life, but lower adherence to ET than patients aged up to 65 years. An important issue for womens’ health is sexual health and in this context, sexual dysfunction affects women besides age group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
269P - Her2-low/HRR proficient early triple negative breast cancer is characterized by good prognosis
Presenter: Benedetta Pellegrino
Session: Poster session 14
270P - Dissecting molecular heterogeneity of luminal breast cancers using an ion mobility DIA proteomic approach
Presenter: Anne Patsouris
Session: Poster session 14
271P - Overall expression of human endogenous retroviruses in early breast cancer and their correlation with immunogenicity
Presenter: Julie Lecuelle
Session: Poster session 14
272P - Modulation of systemic and intratumor metabolism predicts response to fasting-mimicking diet plus chemotherapy in patients with early TNBC
Presenter: Francesca Ligorio
Session: Poster session 14
274P - A multiomic approach for camizestrant-induced estrogen receptor (ER) degradation, antagonism and anti-proliferation: Exploratory analysis from SERENA-3
Presenter: Giorgi Dzagnidze
Session: Poster session 14
275P - Phase II study of pyrotinib plus albumin-bound paclitaxel and trastuzumab (HLX02) as neoadjuvant treatment in HER2-positive, stage II-III breast cancer
Presenter: Ting Luo
Session: Poster session 14
276P - SHR-A1811 in combination with pyrotinib as neoadjuvant treatment for HER2-positive breast cancer (HER2+ BC): Preliminary results from MUKDEN 07
Presenter: Cai Liu
Session: Poster session 14
277P - Long term follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of trastuzumab in patients with HER2-positive breast cancer
Presenter: Jinmei Zhou
Session: Poster session 14
Resources:
Abstract
278P - Prognostic and biologic significance of HER2-low early-stage breast cancer with long-term follow-up
Presenter: Yuka Niwa
Session: Poster session 14
280P - Personalized treatment approaches with HER2DX in early HER2-positive breast cancer: A precision tool for treatment decision-making
Presenter: Marta Tapia Céspedes
Session: Poster session 14